SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-209172
Filing Date
2023-08-10
Accepted
2023-08-10 17:05:31
Documents
13
Period of Report
2023-08-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d538151d8k.htm   iXBRL 8-K 26716
  Complete submission text file 0001193125-23-209172.txt   184740

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20230804.xsd EX-101.SCH 3881
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE qncx-20230804_def.xml EX-101.DEF 13697
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20230804_lab.xml EX-101.LAB 22683
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20230804_pre.xml EX-101.PRE 14665
7 EXTRACTED XBRL INSTANCE DOCUMENT d538151d8k_htm.xml XML 5194
Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 231160541
SIC: 2836 Biological Products, (No Diagnostic Substances)